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Abstract
Purpose This study aimed to develop a utility index (the
ABC-UI) from the Aberrant Behavior Checklist-Commu-
nity (ABC-C), for use in quantifying the benefit of
emerging treatments for fragile X syndrome (FXS).
Methods The ABC-C is a proxy-completed assessment of
behaviour and is a widely used measure in FXS. A subset
of ABC-C items across seven dimensions was identified to
include in health state descriptions. This item reduction
process was based on item performance, factor analysis and
Rasch analysis performed on an observational study data-
set, and consultation with five clinical experts and a
methodological expert. Dimensions were combined into
health states using an orthogonal design and valued using
time trade-off (TTO), with lead-time TTO methods used
where TTO indicated a state valued as worse than dead.
Preference weights were estimated using mean, individual
level, ordinary least squares and random-effects maximum
likelihood estimation [RE (MLE)] regression models.
Results A representative sample of the UK general public
(n = 349; mean age 35.8 years, 58.2 % female) each val-
ued 12 health states. Mean observed values ranged from
0.92 to 0.16 for best to worst health states. The RE (MLE)
model performed best based on number of significant
coefficients and mean absolute error of 0.018. Mean utili-
ties predicted by the model covered a similar range to that
observed.
Conclusions The ABC-UI estimates a wide range of
utilities from patient-level FXS ABC-C data, allowing
estimation of FXS health-related quality of life impact for
economic evaluation from an established FXS clinical trial
instrument.
Keywords Fragile X syndrome  Aberrant Behavior
Checklist  TTO  Lead-time  Utility index
Introduction
Fragile X syndrome (FXS) is a genetic condition caused by
a mutation in the FMR1 gene resulting in cognitive
impairment and behavioural problems [1]. FXS is the most
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common inherited form of intellectual disability, affecting
approximately one in 4,000 males and one in 8,000 females
[2]. Behavioural characteristics include anxiety, aggres-
sion, hyperarousal, attention deficits, hyperactivity, irrita-
bility, self-injurious and avoidant behaviour [3]. Males will
typically have intellectual disabilities linked to below
average IQ. Language deficits are common, as well as
problems with sequential processing, working memory and
attention [4]. Psychiatric problems such as generalised
anxiety disorder, social phobia and obsessive compulsive
disorder were found to occur in 83 % of individuals with
FXS [5]. Approximately 50 % of males with FXS will also
have an autistic spectrum disorder (ASD) [6]. FXS can
exert a substantial burden on caregivers [7], and many
patients are unable to live independently [8].
Recent research has resulted in a new understanding of
the molecular pathways affected by FXS, and a new gen-
eration of targeted treatments is currently being tested in
clinical trials [9, 10]. Given the prevalence of social and
behavioural problems in FXS, one commonly used mea-
sure is the Aberrant Behavior Checklist-Community Edi-
tion (ABC-C), a proxy-completed instrument for rating
maladaptive and inappropriate behaviours of individuals
with intellectual disabilities [11]. It has been shown to be
sensitive in FXS [12–15] and is commonly adopted as a
primary outcome measure in clinical trials [16]. The 58
item ABC-C measures problem behaviour in five domains:
hyperactivity, socially unresponsive/lethargic behaviour,
stereotypy, inappropriate speech and irritability [11].
Recently, an adjusted factor structure for individuals with
FXS has been reported [16], which identified a sixth ABC-
C domain in FXS, which separates out social avoidance
behaviour from socially unresponsive/lethargic behaviour
(ABC for FXS).
While caregiver-rated scales can demonstrate the effi-
cacy of an intervention on key characteristics of FXS, only
limited data are available regarding the impact of FXS on
health-related quality of life (HRQL), particularly for
adults. Many decision makers such as the National Institute
for Health and Care Excellence (NICE) in the UK prefer to
evaluate treatments in terms of impact on survival and
HRQL using the quality-adjusted life year (QALY) metric.
The estimation of QALYs relies upon HRQL scales that
reflect the value (or utility) that people place on health
states on a scale from zero (dead) to one (full health). A
lack of HRQL data and even suitable HRQL measures in
FXS limits ability to estimate QALYs for this condition.
Different methods exist for capturing HRQL data suit-
able for estimating QALYs, the most common of which,
and preferred by reimbursement agencies such as NICE
[17], is use of standardised generic questionnaires where
the patient describes their HRQL in a series of questions.
Scoring/preference weights are applied to these responses
to estimate a utility score. For the purposes of reimburse-
ment review, commonly, it is the societal perspective that
is important [18, 19], so the scoring weights are elicited
from the general public in a separate exercise. Examples of
such measures include the EQ-5D, SF-6D and Health
Utilities Index (HUI) [20–23].
However, generic HRQL measures such as the EQ-5D
(covering mobility, self-care, usual activities, pain/discomfort
and anxiety/depression) may not accurately capture the
impact of certain aspects of FXS, a condition with predomi-
nantly behavioural, social and cognitive characteristics. Also,
the more subjective aspects of HRQL such as mood, affect,
psychological state or pain can be difficult for a proxy to
judge, as evidenced by higher rates of missing data on more
subjective domains completed by parents of children with an
ASD [24]. Agreement between patient and proxy assessments
of HRQL has been found to depend on the concreteness,
visibility and importance of aspects of HRQL [25].
An alternative approach is to develop a utility scoring
algorithm, or index, from an existing disease-specific
measure or one designed to measure problems associated
with certain types of conditions. Disease-specific descrip-
tive systems include items relevant to the patient’s condi-
tion that may not be captured by generic measures [26, 27].
Where a validated disease-/problem-specific measure is
commonly used to capture primary outcome data in clinical
trials, the ability to estimate utilities from these same data
is an added benefit. As the ABC-C in its original form
cannot be used to estimate QALYs, the current study was
designed to develop and evaluate an ABC-utility index
[ABC-UI] to report health state utility scores for children,
adolescents and adults with FXS based on patient-level
responses to the ABC-C.
Methods
Design
Methodological steps to derive a utility index for the ABC-
C followed those described for other condition-specific
preference-weighted scoring algorithms [28, 29] including
reducing the number of items; selecting the best items for
forming a health state classification using psychometric
analysis; reducing the number levels on each item; valuing
a sample of states defined by the health state classification;
and modelling the health state data in order to generate a
scoring algorithm.
Development of health state descriptions
Selection of ABC-C items for health state development
was based on a combination of statistical analysis and
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expert input. Secondary analysis of ABC-C data from a
study involving 350 US FXS caregivers [30] was under-
taken. Thirty-one out of 58 ABC-C items were dropped on
the basis of preliminary statistical analysis using the fol-
lowing considerations: missing data [4 %, evidence of
floor/ceiling effects, item variability (\10 % of responses
on two or more adjacent scale points), range, inter-item
correlation, evidence of cross-loading on two or more
domains and poor factor loading (principle components
analysis, varimax and promax explored). Item selection
was further informed by Rasch analysis on the remaining
items exploring item difficulty and differential item func-
tioning (DIF) for age (children/adolescents vs. adults) and
gender. Little variation in Rasch item difficulty was found
in the dataset (ranging from 1.18 logit (ABC-C:44) to 2.06
logit (ABC-C:53)), providing insufficient guidance for
selecting items covering a range of severity. Nineteen
items showed significant DIF by age and 13 by gender
(p \ 0.05). Guided by the DIF results, items were selected
for consistency in functioning across age and gender.
Five clinical experts (n = 5) with extensive collective
experience of working with individuals with FXS in the
US, UK and Australia (named as co-authors or in
acknowledgements) provided input by reviewing item
selection at two stages and providing feedback via tele-
phone discussion. This process aimed to identify ABC-C
items capturing important aspects of FXS and/or items with
important HRQL impact and was iterative with statistical
analysis. As a result of clinical expert input, Pearson’s
correlations were calculated on the observational dataset
between ABC-C items and anxiety (Anxiety, Depression
and Mood Scale (ADAMS) General Anxiety Subscale,
[31]), IQ, attention problems [(child and adolescent
symptom inventory (CASI) [32], inattentive subscale; or
adult inventory (AI) [33], inattentive subscale] and a single
item global assessment of HRQL to further inform selec-
tion of items that may capture characteristics of FXS and
HRQL impact not covered directly by the ABC-C.
Statistical analysis and expert input resulted in nine
ABC-C items selected as key health dimensions necessary
to describe the primary HRQL impacts of FXS (Table 1).
All nine items are included in the revised scoring/domain
structure of the ABC for FXS [16]. There are four response
options for each item in the ABC-C ranging from 0—not at
all a problem, to 3—severe problem. Analyses identified
that the two most severe response categories (‘moderately
serious’ and ‘severe’) were endorsed infrequently. As a
result, these response categories were combined into a
single response (‘moderately serious/severe problem’), a
decision that was supported by the clinical experts.
Introductory text was used to provide background
information regarding FXS for study participants. This was
piloted along with example health state descriptions with
five members of the UK general public in cognitive debrief
interviews. Following piloting, the heath state descriptions
were further simplified to seven dimensions, combining
items where pilot participants struggled to imagine or rate
states, feeling it was illogical to experience no problems on
one, but serious problems on another. These were two
items related to social avoidance (ABC-C:58 showing few
social reactions to other children or adults; ABC-C:30
isolating yourself from other children or adults) and two
items related to hyperactivity (ABC-C:44 being easily
distractible; ABC-C:15 restless, unable to sit still). Fig-
ure 1 shows an example FXS health state description
derived from the seven-dimension, three-level ABC-C
health state classification system and demonstrates how
ABC-C item content was combined with impact levels to
describe level of impact by dimension.
Health state valuation
The seven-dimension, three-level classification system
gives rise to a possible 2,187 health states. A subset of 18
health states were generated for valuation using a fractional
factorial orthogonal design based on a published array
(http://www2.research.att.com/*njas/oadir/oa.18.7.3.2.ugly.
txt). Best (‘no problems at all’ on all seven dimensions) and
worst (‘moderately serious or severe problems’ on all seven
dimensions) health states were also included. The health
states were randomly allocated into two sets to reduce
Table 1 ABC-C items selected for inclusion in FXS health states,
grouped by ABC-C for FXS Domain [16]
ABC-C for FXS
domains [16]
ABC-C item selected for inclusion
in FXS health states
Irritability ABC-C:4 Aggressive to other
children or adults
(verbally or physically)
ABC-C:36 Mood changes quickly
Socially
unresponsive/
lethargic
ABC-C:58a Shows few social reactions
to others
Stereotypy ABC-C:35 Repetitive hand, body or
head movements
Hyperactivity ABC-C:13 Impulsive (acts without thinking)
ABC-C:15b Restless, unable to sit still
ABC-C:44b Being easily distractible
Social avoidance ABC-C:30a Isolates him/herself from
other children or adults.
Inappropriate
speech
ABC-C:22 Repetitive speech
a Items ABC-C: 58 and ABC-C: 30 combined as a single dimension
in the FXS health states
b Items ABC-C: 15 and ABC-C: 44 combined as a single dimension
in the FXS health states
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responder burden. Each set contained the best and worst
health states plus nine of the orthogonally generated health
states.
After providing informed consent, general public par-
ticipants were randomly allocated to one of the sets of
health states. Participants read the introductory text before
familiarising themselves with the health states by rating
them on a 0–100 visual analogue scale (100 representing
best possible health, zero representing worst possible
health). Each participant was then asked to value the heath
states against full health (being in the best possible state of
health and not having the condition described in the intro-
ductory text). Participants valued each health state using a
conventional TTO approach: participants were asked to
choose whether they would prefer (A) living in generic full
health for a period of time, varying from 0 to 10 years and
then dying (without experiencing any time in the FXS
health state), or (B) living in the health state for 10 years
(remaining in that health state without improving) and then
dying. The amount of time in full health in Life A was
systematically changed by the interviewer until the partic-
ipant indicated that they were indifferent between option A
and option B. To allow for the possibility of health states
being valued as worse than dead, an additional lead-time
TTO (LT-TTO) valuation procedure was used for any
health state where in TTO valuation a participant chose Life
A when the number of years in full health was zero [indi-
cating that the participant would prefer to die than live in the
health state (B)]. In the LT-TTO procedure, participants
chose whether they would prefer: (A) living for a period of
time in full health, varying from 0 to 10 years and then
dying (without experiencing any time in the FXS health
state), or (B) living for 10 years in full health, followed by
10 years in the health state (remaining in that health state
without improving) and then dying. The amount of time in
life (A) was changed until the participant indicated that they
are indifferent between option A and option B. As a sense
check, at the end of any interview where LT-TTO had been
used, participants were asked whether they were aware that
they had valued the relevant state(s) as worse than dead.
The combined TTO and LT-TTO valuation procedures used
here were adapted from methods used for recent EQ-5D-5L
valuation work [34]. In the current study, the valuation task
was facilitated by a double-sided TTO/LT-TTO board.
Sample
Three hundred and forty-nine participants, aged C18 years,
were recruited from the UK general population using con-
venience sampling approaches (e.g. local advertising, word
of mouth/snowballing, volunteers who had participated in
previous research). Recruitment and interviews were con-
ducted in six geographical areas of the UK. Recruitment
aimed for a sample broadly representative of the socio-
demographic profile of the UK general population. Socio-
demographic data were collected using a background form.
Analysis
Valuation data from the two sets of health states were
combined for analysis. Regression models were fitted to the
TTO/LT-TTO data (hereafter referred to as TTO data). The
Fig. 1 Example FXS health
state
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models are specified with level 1 or 2 of each dimension
(‘slight’ and ‘moderately serious/severe’) represented by a
dummy variable and ‘no problem’ the baseline reference
level. These models were used to predict values for all
health states defined by the classification system using the
following additive regression equation:
Uij ¼ gðb0xiÞ þ eij ð1Þ
where U represents TTO, i = 1,2…n represents individual
health states, j = 1,2…m represents respondents, g is a function
specifying the appropriate form, Xi is a vector of binary dummy
variables for each level l of dimension d of the descriptive
system where the best level of each dimension represents the
baseline for that dimension, and eij is an error term, whose
properties depend on the assumptions of the model.
A variety of regression models were fitted to individual
level data and to mean health state values: ordinary least
squares (OLS), random-effects models using maximum
likelihood estimation (MLE) and mean model of one mean
value per state.
Performance of the regression models was assessed
using the number of significant and non-significant coef-
ficients, the consistency of the coefficients with the
descriptive system, root mean squared error (RMSE) at the
individual level and mean absolute error (MAE) at the state
level. The Akaike information criterion (AIC) and Bayes-
ian information criterion (BIC) were also examined. Pre-
dicted values, observed values and errors by health states
were plotted and examined for patterns. The final choice of
model was based on a combination of consistency and
predictive performance.
Results
Sample characteristics
Overall, the sample characteristics were similar to census
and reference data (Table 2). However, the sample was
slightly younger (mean 35.8 years vs. mean England and
Wales age 38.6 years [35]), included more women (58.2 %
vs. 50.8 % [36]) and were more educated (54.2 % com-
pleted university vs. 27 % of the UK population have a
degree-level qualification [36]).
Observed values for health states
The mean utility for the best health state was 0.92 [standard
deviation (SD) 0.14, 95 % confidence intervals (CIs) 0.90,
0.93]. The mean utility for the worst health state was 0.16
(SD 0.47, 95 % CIs 0.11, 0.21). Mean values for all other
health states fell within this range (Table 3).
Regression analysis results
All models produced parameter coefficients indicating
decrements in utility consistent with the descriptive system
(i.e. all coefficients were positive, Table 4). The number of
significant parameter coefficients in each model shows the
importance of different dimensions. The OLS mean model
produced fewest significant coefficients (Model 3,
Table 4). Individual level models produced marginally
lower MAEs. The absolute level of error of 0.018 compares
well with previous studies using TTO to value condition-
specific scales [37, 38]. None of the models show evidence
of logical inconsistencies in the parameter values.
The RE (MLE) model (Model 2, Table 4) performed
slightly better than other models and is also preferred due
to its ability to accommodate the repeated measures aspect
of the data. Values estimated by the RE (MLE) model
Table 2 Socio-demographic sample characteristics [n = 349]
Age [years] Mean [standard deviation] 35.82 [14.22]
Median [range] 31.00 [18–83]
Gender n [%]a Male 144 [41.3]
Female 203 [58.2]
Quality of life
(EQ-5D-3L utility)
Mean [standard deviation] 0.95 [0.09]
Ethnicity n [%] White 323 [92.6]
Mixed or multiple ethnic
groups
11 [3.1]
Asian or Asian British 10 [2.9]
Black or Black British 1 [0.3]
Any other ethnic group 4 [1.1]
Employment
status n [%]
Employed full or part-time 244 [69.9]
Student 45 [12.9]
Seeking work/unemployed 16 [4.6]
Retired 20 [5.7]
Stay at home 9 [2.6]
Other 15 [4.3]
Highest level of
education n [%]
No formal qualifications 11 [3.1]
Left school at 16 27 [7.7]
Left school at 18 44 [12.6]
Technical/vocational 61 [17.5]
Completed university 189 [54.2]
Other 17 [4.9]
Ever experienced a
serious illness
n [%]
Yes, in yourself 34 [9.7]
Yes, in your family 207 [59.3]
Yes, in caring for others 87 [24.9]
a Missing data n = 2
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closely fit observed mean values for health states with little
evidence for any systematic pattern to the errors produced
(Fig. 2). The range in mean health state values predicted by
the RE (MLE) model, 0.92 (best) to 0.21 (worst), is similar
to the observed range.
ABC-C utility index (ABC-UI)
Using the constant and parameter coefficients from the RE
(MLE) model (Model 2, Table 4), a utility score is calcu-
lated by subtracting from full health (i.e. 1) the constant
term and the decrement associated with the level on each
dimension. The following algorithm shows how to estimate
an ABC-UI score from patient-level ABC-C data:
U ¼ 1  Constant 0:079½ 
 ABC36 0 ¼ 0; 1 ¼ 0:025; 2 or 3 ¼ 0:083½ 
 MAX ABC15; ABC44½ 
0 ¼ 0; 1 ¼ 0:009; 2 or 3 ¼ 0:054½ 
 ABC4 0 ¼ 0; 1 ¼ 0:065; 2 or 3 ¼ 0:239½ 
 ABC13 0 ¼ 0; 1 ¼ 0:026; 2 or 3 ¼ 0:048½ 
 ABC22 0 ¼ 0; 1 ¼ 0:022; 2 or 3 ¼ 0:059½ 
 MAX ABC30; ABC58½ 
0 ¼ 0; 1 ¼ 0:025; 2 or 3 ¼ 0:129½ 
 ABC35 0 ¼ 0; 1 ¼ 0:028; 2 or 3 ¼ 0:098½ 
where U represents the utility value, ABC36 represents the
score on ABC-C:36 (Mood changes quickly) and similarly
ABC4 (ABC-C:4 score, aggressive to other children or
adults (verbally or physically)); ABC13 (ABC-C:13 score,
impulsive (acts without thinking); ABC22 (ABC-C:22
score, repetitive speech); ABC35 (ABC-C:35 score, repet-
itive hand, body or head movements). MAX (ABC15,
ABC44) represents the highest score out of ABC-C:15
(restless, unable to sit still) and ABC-C:44 (being easily
distractible), and similarly, MAX (ABC30, ABC58) repre-
sents the highest score out of ABC-C:30 (isolates him/
herself from other children or adults) and ABC-C:58
(shows few social reactions to others).
Discussion
This study was designed to develop a utility index for the
ABC-C, an established outcome measure commonly used
in the assessment of FXS. This utility index allows the
estimation of values at the individual patient level within
the range of 0.92–0.21, reflecting substantial perceived
HRQL burden of problems.
The utility index was developed using relatively stan-
dard methodology where a subset of items from a validated
psychometric outcome measure are used to describe health
Table 3 Observed values for
health state descriptions
a Classification: health state
description by level of
impairment on ABC-C items
that relate to the seven health
state dimensions: zero [no
problems], one [slight
problems] or two [moderately
serious or severe]. For example,
health state two [2122220]
describes moderately serious or
severe problems on dimensions
one and three to six, slight
problems on dimension two and
no problems on dimension
seven
See Table 4 for dimensions and
corresponding ABC-C items
and Fig. 1 for how health states
were described for valuation
Sample size: health state
descriptions 1 and 20, n = 349;
3, 4, 6, 7, 10, 11, 14, 18 and 19,
n = 174; 2, 5, 8, 9, 12, 13, 15,
16 and 17, n = 175
Health state description Mean Standard
deviation
Minimum Maximum 95 %
Confidence
intervals
Percentage of
participants who
valued state \0
Classificationa
1 2 2 2 2 2 2 2 [Worst] 0.16 0.47 -1.00 0.98 0.11 0.21 15.8
2 2 1 2 2 2 2 0 0.41 0.36 -1.00 0.98 0.36 0.47 4.0
3 2 2 1 1 2 2 2 0.43 0.40 -1.00 1.00 0.37 0.49 5.2
4 0 2 2 0 0 2 1 0.50 0.34 -1.00 0.98 0.45 0.55 2.9
5 0 0 2 0 2 1 2 0.51 0.32 -1.00 0.98 0.46 0.56 2.3
6 2 0 2 2 1 0 1 0.51 0.39 -1.00 0.98 0.45 0.56 4.6
7 1 1 2 1 0 0 2 0.53 0.36 -1.00 0.98 0.48 0.58 4.0
8 1 2 2 1 1 1 0 0.53 0.35 -1.00 0.98 0.48 0.58 4.0
9 1 0 0 2 0 2 2 0.65 0.27 -1.00 0.98 0.61 0.69 1.1
10 0 1 1 2 1 1 2 0.67 0.26 -1.00 0.98 0.63 0.70 0.6
11 1 0 1 0 1 2 0 0.67 0.24 -0.55 0.98 0.64 0.71 0.6
12 0 1 0 1 1 2 1 0.69 0.25 -0.73 1.00 0.65 0.72 1.1
13 2 0 1 1 0 1 1 0.69 0.26 -1.00 0.98 0.65 0.73 1.1
14 1 2 0 2 2 1 1 0.70 0.23 0.08 0.98 0.67 0.73 0
15 2 2 0 0 1 0 2 0.70 0.26 -1.00 0.98 0.67 0.74 0.6
16 1 1 1 0 2 0 1 0.71 0.25 -1.00 0.98 0.68 0.75 0.6
17 0 2 1 2 0 0 0 0.75 0.18 0.18 0.98 0.72 0.78 0
18 2 1 0 0 0 1 0 0.79 0.18 0.00 0.98 0.76 0.81 0
19 0 0 0 1 2 0 0 0.84 0.16 0.28 1.00 0.82 0.87 0
20 0 0 0 0 0 0 0 [Best] 0.92 0.14 0.23 1.00 0.90 0.93 0
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states for societal valuation. Without reducing the number
of items, the valuation task would be impossibly complex
and reduction of the complexity of an existing psycho-
metric instrument is an approach common to the
development of other utility indexes [28, 29]. However, the
ABC-C is unusual in the extent to which the measure had
to be reduced. The original instrument included 58 items
[11], which meant that 80–90 % of original items had to be
discarded to achieve a health state classification system of
sufficient simplicity for valuation. This presented a sig-
nificant challenge for retaining the validity and scope of the
ABC-C.
To address this challenge, the item reduction process
was guided by a number of different sources of evidence,
including advanced statistical methods and expert review.
Care was taken to identify items capturing a range of
severity in aspects of FXS that affect males and females,
children and adults, are related to cognitive and emotional
characteristics of FXS and have wider impact for individ-
uals’ HRQL. However, it should be noted that the item
selection process was for the purpose of developing a
utility index for HRQL and cannot be considered to reflect
the entire ABC-C measure or aspects of FXS not captured
by the ABC-C. As a result, although the ABC-UI reported
here draws on items across the ABC-C domains [11, 16], it
Table 4 Regression model
estimations of weights for
dimension levels
OLS ordinary least squares, RE
[MLE] random effects
maximum likelihood estimation,
MAE mean absolute error, AIC
Akaike information criterion,
BIC Bayesian information
criterion
** p \ 0.01, * p \ 0.05
a Due to the method of
estimation, the RE [MLE]
models do not produce an
R-square
Health state
dimension
ABC-C item Variables [1] [2] [3]
OLS RE
[MLE]
Mean
OLS
1 ABC-C:36 Mood1 0.025 0.025* 0.025
Mood changes quickly Mood2 0.083** 0.083** 0.082*
2 ABC-C:44, ABC-C:15 Distractible1 0.009 0.009 0.010
Easily distractible or restless, unable to sit
still
Distractible2 0.054** 0.054** 0.055
3 ABC-C:4 Aggressive1 0.065** 0.065** 0.067
Aggressive towards others [verbally and
physically]
Aggressive2 0.239** 0.239** 0.239**
4 ABC-C:13 Impulsive1 0.026* 0.026** 0.028
Being impulsive, [acting without
thinking]
Impulsive2 0.048** 0.048** 0.049
5 ABC-C:22 Speech1 0.022 0.022* 0.023
Repetitive speech Speech2 0.060** 0.059** 0.060
6 ABC-C:58 ABC-C:30 Social1 0.025 0.025* 0.026
Shows few social reactions to others and
isolating yourself from others
Social2 0.129** 0.129** 0.129**
7 ABC-C:35 Movements1 0.028* 0.028** 0.030
Repetitive hand, body or head movements Movements2 0.098** 0.098** 0.099*
Constant 0.079** 0.079** 0.075
Observations 3,430 3,430 20
R-squareda 0.267 0.974
Inconsistencies 0 0 0
Sig.
coefficients
14 14 5
MAE 0.018 0.018 0.020
AIC 1,444 228 -56
BIC 1,536 332 -41
Fig. 2 Observed and predicted health state values from the RE
(MLE) model
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is designed to complement the profile of validated domain
scores derived from the ABC-C and cannot be considered a
proxy for a total ABC-C score, which is not considered an
appropriate or valid summary score to calculate [39, 40].
In the FXS treatment context, there are several reasons
why a preference-weighted adaptation of the ABC-C may
better estimate utilities than an existing generic preference-
weighted measure such as EQ-5D [21]. For example, the
proxy-rated version of EQ-5D could have been used for
assessing health status of adults and the proxy-rated EQ-
5D-Y [41] could have been used with children and young
people. However, the ABC-C is specific to the problems
people with FXS experience, comprising conceptually very
different items to those in the EQ-5D and thus has the
potential to better assess the impact of disease and treat-
ment. Secondly, the ABC-C was developed and validated
as a proxy-rated measure, whereas the EQ-5D was only
adapted for proxy use and the evidence to support its
validity as a proxy-rated measure is limited. Indeed, there
is evidence that the proxy-rated EQ-5D has poor reliability
when assessing more subjective elements of health status
(such as anxiety/depression and pain/discomfort) [42]. The
ABC-UI offers reduced measurement burden to future
clinical trials in FXS with the possibility of using a single
outcome measure, as well as the potential to estimate utility
values from existing ABC-C FXS datasets.
One notable aspect of the study design is the use of a
combined TTO and lead-time TTO (LT-TTO) valuation
method. The conventional TTO approach only allows
states to be valued as better than dead, requiring the
investigator to use a substantially different valuation task
for states worse than dead [43]. LT-TTO offers a simpler
method which is compatible with conventional TTO [44].
In the present study, the combined TTO and LT-TTO
approach appears to have worked well. It was well
understood by participants, and there were no obvious
patterns of systematic bias in the results. Valuations by
some participants in the present study that indicated a
belief that certain health states were worse than being dead,
were supported by interview field notes confirming that
these participants understood the implications of their
valuation, e.g. participants were concerned about caregiver
burden and potential institutionalisation if behaviour was
considered sufficiently severe.
A further methodological issue is the fact that FXS
affects both children and adults. The valuation of child
health states leads to some points for debate. Should adult
participants value states knowing that they describe chil-
dren or should they be asked to assume they are adult
states? Should valuation of such states be restricted to
parents because they have greater insight into the needs of
children? Should the views or values of children them-
selves be sought? In this study, adult members of the
general public were asked to value health states by imag-
ining they are in the health state, i.e. as if they are an adult
patient. This approach was taken for a number of reasons.
Firstly, the ABC-C is used with children and adults and is
not just a paediatric measure. Secondly, asking people to
imagine that they are a child with symptoms of FXS raises
concerns about introduction of bias in the data. It is not
clear that people would be willing to trade years of a
child’s life (even hypothetically) in order to improve their
HRQL and it becomes unclear what the participant would
be valuing in such an exercise. There is relatively little
research that has properly addressed these issues, and it is
clear that this is needed [45].
The present study has the following limitations which
should be considered. It is unclear how the ABC-UI per-
forms compared with other utility measures. This may well
be important for decision-making in a reimbursement set-
ting. One important issue is that the ABC-C is primarily a
measure of behavioural problems rather than a measure
focused on capturing HRQL. The QALY concept explicitly
reflects survival and HRQL, and therefore, it could be
argued that the ABC-UI has limitations when used to
estimate QALYs. It could equally be argued that because
of the nature of FXS, people’s HRQL is in large part
determined by their behavioural and functional problems.
However, in the valuation exercise, the respondents were
provided with little or no information regarding aspects of
HRQL not covered in the descriptive system, such as
physical functioning. This could potentially be interpreted
in different ways by respondents. This is perhaps a general
limitation in the use of condition-specific measures to
estimate utilities. Condition-specific measures offer the
advantage of including potentially specific and sensitive
items to assess the burden of a disease, but at the same
time, may miss important elements of HRQL that are not
affected in that disease. While it should be noted that
identifying items with important HRQL impact for people
with FXS was a key aim of the clinical expert review and
item selection/health state development process for the
ABC-UI, this does not change the fact that the ABC-UI
does not specifically include aspects of HRQL commonly
included in generic instruments such as physical func-
tioning (e.g. mobility), emotional status (e.g. anxiety/
depression), self-care and usual activities.
A related concern is the possibility that the focus of the
ABC-C on behavioural problems rather than generic
HRQL domains may have given rise to health states con-
taining impacts which members of the general public may
find hard to understand or value. In the current study,
introductory text was developed with clinical expert review
and input to provide background information that would
help the participants’ understanding of the health states, but
without naming the FXS condition. This was piloted
312 Qual Life Res (2015) 24:305–314
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alongside example health states, with specific probing in
pilot interviews for problematic terms and difficulties
general public participants may have imagining the health
states described. Another potential limitation of this
method is the reliance on proxy assessment for the com-
pletion of the ABC-C. However, given the nature of FXS,
this remains the only realistic option for data collection.
In addition to behavioural problems, FXS is also charac-
terised by anxiety and attention problems [3, 5], which the
ABC-C is not specifically designed to capture. While this
may limit the ability of the ABC-UI to reflect HRQL impact
associated with less behaviourally expressed impacts, mea-
sures of anxiety and attention have been found to be highly
associated with behavioural problems captured by the ABC-
C in FXS, which suggest these characteristics co-occur with
and may drive problematic behaviour observed [30]. Spe-
cific associations between ABC-C items and measures of
non-behavioural FXS characteristics, including anxiety and
attention problems, were also considered in developing the
ABC-UI. Item selection was informed by the ABC for FXS
social avoidance subscale [16]. However, it is possible that
the behavioural focus of ABC-C socially unresponsive/
social avoidance items may not characterise the specific
social difficulties experienced by FXS patients, who typi-
cally seek out but struggle to cope with social situations
rather than avoid or are disinterested in social interaction.
It should be noted that this work was conducted in the
UK and that additional validation work may need to be
conducted in other geographical areas. The UK general
public sample was a convenience sample designed to
approximate the general population. However, the sample
differed slightly from UK general population norms.
Regression models run with additional socio-demographic
variables resulted in a number of the lower levels of health
state dimensions becoming non-significant and showed
significant effects of gender, employment and pain/dis-
comfort (on EQ-5D). This suggests that the small differ-
ences in the sample from the general population may have
had some influence on the results. However, the sizes of the
parameter coefficients for the health state dimensions were
very similar in the models that also included socio-demo-
graphic variables to those reported in Table 4.
Other limitations include the decision during health state
development to merge the two most severe ABC-C health
states. This was made on the grounds that these were
infrequently endorsed in FXS, an observation that was
confirmed by expert clinical input. However, it is possible
that the resulting ABC-UI may lack sensitivity or demon-
strate floor effects when applied to ABC-C scores from
more severe FXS cases. The study also used an orthogonal
design and the resulting ABC-UI assumes a linear additive
functional form. This is not ideal given likely interactions
among participants’ preferences across the seven health
state dimensions. However, this is a common limitation of
most preference-based measures, generic or condition-
specific. Where attempts have been made to address non-
additivity, these have not allowed for interactions between
specific dimensions, but have instead assumed a constant
impact that is either additive or multiplicative. To model
specific interactions between dimensions requires a far
larger sample size.
In conclusion, the ABC-UI appears to be able to report a
wide range of utility values from patient-level FXS ABC-C
data. This allows estimation of FXS HRQL impact for
economic evaluation using an established instrument
commonly adopted as a primary outcome measure in FXS
clinical trials. However, development of a utility index
from a lengthy proxy-rated measure of behaviour raises
both conceptual and methodological challenges, along with
questions over what the index captures and whether this is
an appropriate basis from which to estimate QALYs.
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